BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Asia Pacific on the Brink of a Healthcare Transformation with the Arrival of the Precision Era

The Precision Era of medicine is arriving in Asia Pacific, driven by the arrival of a critical mass of innovative therapies that will redefine treatment, a...

July 22, 2025 | News

Smart Implants and the Future of Musculoskeletal Injury Treatment

While these methods are structurally effective, they cannot adapt to each patient's recovery process or provide insight into the progression of healing. Th...

July 21, 2025 | News

BioPharma in APAC: Mid-Year Report 2025 – Tracking Progress, Trends & Possibilities Ahead

As we cross the midpoint of 2025, BioPharma APAC presents this Mid-Year Report—an incisive look at emerging biopharmaceutical dynamics, key i...

July 21, 2025 | Analysis

The Evolving Landscape of Women’s Health Innovation in the Asia-Pacific

The region’s women’s digital health market is projected to grow to $ 2,295.7 million by 2030, according to Grand View Research. This surge refl...

July 17, 2025 | News

Using NLP-Driven Decision Support in Emergency Health Assistance

According to the US Department of Transportation, over 40,000 lives were lost in roadway deaths in 2023. The CDC reports that the country saw appro...

July 14, 2025 | News

No More Whisper Networks: FDA Puts Its Rejection Reasons in Writing — Publicly

FDA Embraces Radical Transparency by Publishing Complete Response Letters For Immediate Release: July 10, 2025 &nb...

July 11, 2025 | News

FDA’s Most Recent 100 Warning Letters of 2025 Signal Rising Compliance Risks Across Pharma, Biologics, Devices, Food, and Online Markets

As of July 2025, the U.S. Food and Drug Administration (FDA) has issued over 3,400 warning letters, with the most recent 100 painting a vivid pictu...

July 11, 2025 | Analysis | By BioPharma APAC Desk

FDA Finalises Guidance on Drug Development for Early Lyme Disease: A Strategic Signal for Industry Innovation

This finalised guidance serves as a blueprint for biopharmaceutical developers aiming to address early manifestations of Lyme disease—particularly ea...

July 11, 2025 | Analysis | By BioPharma APAC Desk

FDA’s AI Transition Marks a Turning Point in Drug Review: Industry Faces Pressure to Adapt Amid 20% Workforce Cut

The FDA’s recent decision to cut its workforce by 20 percent has raised concerns across the biopharma industry, with experts warning of inevitable de...

July 09, 2025 | Opinion | By Lindsay Mateo, Chief Commercial Officer at Weave Bio

Smarter Together: How Molecule GEN Transforms Cross-Functional Drug Discovery

This cloud-native, SaaS-based platform breaks down traditional barriers in drug discovery by uniting all disciplines—biology, chemistry, and computat...

July 07, 2025 | Opinion | By Saurabh Singal | CEO-Founder, Molecule AI

Taiwan Steps Into the Global Spotlight With a New Cancer Therapy

Traditional therapies often fall short in targeting these aggressive cancers with precision or safety. Can SOB100 improve drug delivery without the usual s...

July 02, 2025 | Report

The Role of Unique Device Identification (UDI) in Tracing Medical Device Safety

According to GlobeNewswire, this vital sector is projected to reach an impressive $756.59 billion by 2031, exhibiting a CAGR of 5.8% from 2024 to 2031. How...

July 02, 2025 | Report

The Importance of a Patient’s Mental Health During Clinical Trials

Most trial participants already have existing health issues. The added burden of trial participation can impact their emotional and psychological well-bein...

July 02, 2025 | Report

Southeast Asia Poised to Lead AI-Driven Healthcare Transformation Amid Rising Cross-Border Collaboration

The Southeast Asia (SEA) region’s role in healthcare innovation, long bolstered by Singapore’s commitment to serve as a g...

July 01, 2025 | Opinion | By Chu Canh Chieu, FPT Software Managing Director of Global Healthcare Center, FPT Corporation

Stay Connected